Inactive Instrument

Company SenzaGen AB Nasdaq Stockholm

Equities

SE0010219626

Biotechnology & Medical Research

Business Summary

SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.

Sales per Business

SEK in Million2022Weight2023Weight Delta
Genomic Allergen Rapid Detection
100.0 %
42 100.0 % 50 100.0 % +19.39%

Sales per region

SEK in Million2022Weight2023Weight Delta
Sweden
100.0 %
42 100.0 % 50 100.0 % +19.39%

Managers

Managers TitleAgeSince
Chief Executive Officer 50 17-12-31
Director of Finance/CFO 63 16-10-31
Chief Tech/Sci/R&D Officer 42 13-12-31
Director/Board Member 59 14-10-14
Public Communications Contact 56 17-12-31
Human Resources Officer 59 19-12-31
Corporate Officer/Principal 51 16-12-31

Members of the board

Members of the board TitleAgeSince
Founder 76 10-08-17
Director/Board Member 59 14-10-14
Director/Board Member 62 19-12-31
Director/Board Member 65 19-12-31
Chief Executive Officer 50 17-12-31
Director/Board Member 74 14-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 24,188,325 14,889,392 ( 61.56 %) 0 61.56 %

Company contact information

SenzaGen AB

Medicon Village Building 401

223 81, Lund

+46 4 62 75 60 00

http://www.senzagen.com
address SenzaGen AB